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Intercellular communication has recently been shown to occur via transfer of cargo loaded within extracellular vesicles (EVs). Present
within all biofluids of the body, EVs can contain various signaling factors, including coding and noncoding RNAs (e.g., mRNA, miRNA,
lncRNA, snRNA, tRNA, yRNA), DNA, proteins, and enzymes. Multiple types of cells appear to be capable of releasing EVs, including
cancer, stem, epithelial, immune, glial, and neuronal cells. However, the functional impact of these circulating signals among neural
networks within the brain has been difficult to establish given the complexity of cellular populations involved in release and uptake, as
well as inherent limitations of examining a biofluid. In this brief commentary, we provide an analysis of the conceptual and technical
considerations that limit our current understanding of signalingmediated by circulating EVs relative to their impact on neural function.
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Introduction
In recent years, the extracellular vesicle (EV) field has vastly ex-
panded, with findings providing functional implications for both
normal physiological and pathological states. Whereas initial in-
vestigations assumed that cellular-derived EVs only contained
debris, growing evidence has established that these compart-
ments are enriched with a variety of signalingmolecules that play
crucial roles in many processes (Robbins andMorelli, 2014; Tur-
turici et al., 2014; Budnik et al., 2016; Kra¨mer-Albers and Hill,
2016). Beginning in the 1950s, electronmicroscopy studies of the
CNS suggested the presence of EVs localized within the extracel-
lular space of the brain, with visualization of small vesicles and
multivesicular bodies at the cellular-ventricular interface and no-
tation of cytoplasmic organelles containing RNA granules (Max-
well and Pease, 1956; Cupedo, 1977; Ribas, 1977). However, any
known significance of these vesicles was not elucidated until
more recently. In this Dual Perspectives piece, we first focus on
the findings driving our understanding of EV signaling; and
thereafter, we discuss technical limitations and considerations
that have restricted our ability to ascertain a definitive role for
EVs in brain function. However, despite these limitations, an
optimistic view of the future is critically maintained as novel
technologies and perspectives continue to push boundaries and
advance the EV field forward.
Function of EVs: brief overview of the field
Agroundbreaking study in the immunology field established that
dendritic cells release EVs containing tumor antigens, which in-
duce an immune response to suppress tumor growth (Zitvogel et
al., 1998). Further studies have documented the role of EVs in
mediating some immune-related responses of microglia, B lym-
phocytes, dendritic cells, T cells, macrophages, and astrocytes
(The´ry et al., 1999; Denzer et al., 2000; Robbins and Morelli,
2014). In 2007, Valadi et al. (2007) first demonstrated extracellu-
lar transfer of RNAs between mast cells. In their investigations,
they showed that mast cell-derived EVs contained both mRNAs
and miRNAs, and the mRNA from a mouse mast cell was dem-
onstrated to incorporate into a humanmast cell line, resulting in
expression of the representative protein. Therefore, these studies
confirmed bothmRNAuptake and subsequent translation by the
recipient cell (Valadi et al., 2007), a seminal finding that has
greatly advanced the field. More recently, EVs have also been
shown to prevent antibody-mediated neutralization of encapsu-
lated viral particles, thereby allowing for the propagation of viral
infection (Bello-Morales et al., 2018). Additionally, during an
activated neuroimmune response, both microglia and astrocytes
release EVs that contain the cytokine interleukin-1 (IL-1),
which further contributes to immune signaling (Bianco et al.,
2005, 2009; Colombo et al., 2018). EVs released from microglia
also contain other signaling factors related to the immune re-
sponse, including major histocompatibility Class II receptors,
CD13, TNF, caspase 1, metalloproteinases, tetraspanins, and
chaperones (Potolicchio et al., 2005; Robbins and Morelli, 2014;
Budnik et al., 2016).Microglia have also been found to propagate
the aberrant inflammatory response in multiple sclerosis animal
models (Zrzavy et al., 2017), which might in part result from EV
cargo uptake into neurons (Prada et al., 2018). Of further inter-
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est, microglia-derived EVs have been implicated in synaptic plas-
ticity and in processes related to Alzheimer’s disease pathology
(Antonucci et al., 2012; Yuyama and Igarashi, 2017). For exam-
ple, activation of microglia serotonin receptors results in the re-
lease of EVs containing insulin-degrading enzyme along with
decreased expression of amyloid- (Glebov et al., 2015); this
finding is consistent with the documented correlation in humans
between high levels of serotonin and reduced levels of amyloid-
in patients (Cirrito et al., 2011).
Within the cancer field, a foundational understanding of EV
signaling has also been achieved given the ability to examine iso-
lated cells in culture conditions. Interestingly, oncogenic-related
signaling increases the release of EVs from cancer cells, and their
EV cargo includes cancer-related proteins, RNA transcripts,
and/or genomic DNA; surprisingly, these factors may align with
either tumor-promoting or suppressor functions (Yu et al., 2005;
Lee et al., 2014; Nakano et al., 2015). Of further note, EVs can
mediate metastases in recipient cells (McAllister and Weinberg,
2014; Nogue´s et al., 2018), and the pattern of integrins on the EV
surface appears to determine specificity of target organ trophism
(Hoshino et al., 2015). With relevance to the brain, the highly
aggressive and malignant glioblastoma cancer cell line has been
shown to release EVs that contain miRNAs, mRNAs, histones,
and various proteins, which may then affect tumor growth (Skog
et al., 2008; Nakano et al., 2015).
EV interactions betweenneurons and glia have also been iden-
tified with in vitro studies. Early seminal studies found that cul-
tured neurons release EVs (Faure´ et al., 2006), and subsequent
investigations have shown that EVs are released from somato-
dendritic compartments in response to depolarization in culture
conditions (Faure´ et al., 2006; Lachenal et al., 2011). EV uptake
has been demonstrated to depend on both the EV characteristics
and the recipient cell. For example, neuroblastoma-derived EVs
appear to be selectively endocytosed by glial cells, whereas EVs
released from neurons are preferentially taken up by other neu-
rons in culture (Chivet et al., 2014). These important findings
have advanced the theory that cell type-specific interneuronal
communication via EVs may mediate information processing
within the brain. In addition, oligodendrocytes have also been
shown to assist in maintaining neuronal health through EV sig-
naling. Oligodendrocyte-derived EVs alter neuronal firing rate
and enhance neuronal viability under conditions of oxygen and
glucose deprivation, as assessed in transwell coculture conditions
(Fru¨hbeis et al., 2013; Frohlich et al., 2014). NMDA and AMPA
glutamate receptors on both neurons and glial cells have been
implicated in this EV release, which was demonstrated via phar-
macological approaches in culture (Lachenal et al., 2011; Fru¨h-
beis et al., 2013; Chivet et al., 2014; Frohlich et al., 2014).
Furthermore, EV communication across short distances, such as
the synaptic cleft, has been demonstrated as a means of intercel-
lular RNA transfer (Pastuzyn et al., 2018). Finally, EV-mediated
signaling can occur between peripheral and neuronal cells. At the
neuromuscular junction, retrograde signaling via EV transmis-
sion has been demonstrated in Drosophila (Korkut et al., 2013),
and hematopoietic-derived EVs have been shown to enter the
brain under some inflammatory conditions, which can result in
EV miRNA uptake into neurons in mice (Ridder et al., 2014).
Together, the findings to date have provided a basis of knowl-
edge suggesting a possible role for EV signaling in the brain, but it
is important to note that these data are mainly based on cell
culture conditions, which may not be representative of endoge-
nous mechanisms in a complex biological system, such as the
brain or other multicellular organ. Indeed, the functional impact
of circulating EVs among neural networks within the brain has
remained difficult to establish given the complexity of cellular
populations involved in release and uptake, as well as conceptual
and technical limitations of the current approaches to analyze EV
characteristics and cargo. In the following paragraphs, we discuss
these considerations to highlight the current barriers in our abil-
ity to draw firm conclusions regarding EV function relative to the
dynamic processes occurring in an intact animal.
General EV considerations
When investigating the potential impact of EV signaling in the
brain, it is important to consider the fact that cargos might vary
between cells and/or within a given cell population across time.
Specifically, many cell types have been shown to release EVs,
including immune, tumor, stem, epithelial, glial, and neuronal
cells (Kosaka et al., 2010; Turturici et al., 2014; Pastuzyn et al.,
2018). The resulting EVs from each cell type may, or may not,
differ in content and function. Furthermore, the releasing cell
may alter the content/function of EV cargo across time based on
varying stimuli and signaling mechanisms. After release into the
extracellular space, EVs have been suggested to (1) immediately
breakdown to dump contents into the interstitial fluid, (2) travel
a short distance to integrate within a cell in close proximity (e.g.,
across the synapse), or (3) travel a longer distance to integrate
into a distant cell population, either through random integration
or via a cell-specific targeting motif. Subsequent cellular integra-
tion may then lead to changes in target cells via the transfer of
proteins, enzymes, DNA, and/or RNA transcripts (e.g., mRNA,
miRNA, lncRNA, snRNA, tRNA, yRNA). As noted above, pro-
tein and gene expression has been shown to become altered fol-
lowing EV transfer of mRNAs or miRNAs, respectively (Kosaka
et al., 2010; Cai et al., 2013; Turturici et al., 2014). Thus far,
however, the potential importance of EVs in normal brain func-
tion has been difficult to clearly define. For instance, the presence
of a vesicle cannot by itself provide evidence of function or rele-
vance for cellular processes since the vesicle might immediately
enter the lysosomal degradation pathway after cellular uptake.
Moreover, even if EV cargo affects cellular processes, the impact
might not be sufficient to exert a measurable effect on cellular
function.
Another concern regarding the potential relevance of EV sig-
naling involves the amount of cargo that can be loaded into the
vesicle. While this may be of less concern for smaller molecules,
such as miRNAs, the transfer of larger molecules, such as mR-
NAs, within a vesicle may only occur on a 1:1 basis, thus limiting
the net impact on a target cell; however, this is admittedly depen-
dent on the number of EVs released, which can be quite substan-
tial. The relative abundance of each type of RNA within a given
population of EVs is an additional point of concern; for instance,
miRNAs may be less abundant in some populations, leading
them to be more challenging to detect when performing mea-
surements based on total RNA in a biological sample (Akers et al.,
2013; Chevillet et al., 2014). Furthermore, despite the finding that
cells can translate extracellularly derived mRNAs into proteins
(Valadi et al., 2007), machinery to further amplify themRNA has
not yet been identified in a recipient cell, indicating that only one
protein could conceivably be produced per mRNA transcript.
Thus, the impact of a singular protein product within a cell may
not result in a significant functional difference. Moreover, any
signaling impact would be expected to be limited within a given
space and time period. As an example, a released EV may prefer-
entially integrate into an adjacent recipient cell based on “first
contact,” or may travel a longer distance to achieve integration
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based on “target preference”; alternatively, there may be compe-
tition between export out of the brain for subsequent elimination
from the body relative to uptake into a target cell, leading to a
smaller percentage of EVs actually becoming involved in a func-
tionally significant signaling process. Regarding time-dependent
limitations, the impact on the recipient cell would be restricted to
the duration of time required for RNA-mediated effects, as it
would be unlikely for the target cell to retain the RNA long-term.
On the other hand, one must also consider that a larger quantity
of cargo does not necessarily imply increased biological rele-
vance. Limited cellular uptake of cargo from the extracellular
environment might have the potential to significantly affect neu-
ral function, depending on the downstream intracellular pro-
cesses (Al-Nedawi et al., 2008). For instance, if the RNA cargo
targets a transcription factor that modulates multiple genes in-
volved inmaintaining cellular function, the resulting effect could
lead to changes in a diverse number of cellular processes.
Heterogeneity of EVs
Heterogeneity of EV populations has become an increasingly in-
tense area of focus since it would be highly desirable to identify
biomarkers for EVs released from a specific cell population.
However, the large variety of EVs with varying characteristics
brings into question what processes can actually be precisely
identified in a complex cellular environment, especially given
that heterogeneity of EVs exists not only across parent cell pop-
ulations but also as released from a single-cell type (Zabeo et al.,
2017). Although studies have classified EVs based on size, cargo,
membrane proteins, targeting motifs, and originating cell popu-
lation, these categorizations have inherent limitations due to
overlapping population characteristics. Several cell types may
preferentially release EVs in the 75–150 nm range or with specific
membrane markers, such as CD63 or CD81. Quantification of
EVs may also not allow for detection of smaller, but biologically
significant, changes in EVs released from the cell population(s) of
interest, based on the relative “signal-to-noise ratio” in the sam-
ple. Moreover, contamination from other tissues may confound
analyses. For example, given that the blood–brain barrier (BBB)
may become disrupted during inflammation, stress, or disease
states, bidirectional transfer of EVs across this barrier can occur,
resulting in both the increased presence of neural-derived EVs in
the blood as well as the reciprocal increased presence of periph-
erally derived EVs in the brain.
EV isolation for characterization
While recent technological advances have permitted more in-
depth interrogation of isolated EVswith higher precision (Shao et
al., 2018), the ability to characterize centrally derived EV popu-
lations from biologically relevant samples remains challenging.
One major factor is the large volume (e.g., 5 ml) of starting
sample required for preferred isolation techniques, such as ultra-
centrifugation or sucrose-gradient centrifugation. Higher purity
with these approaches also comes at a cost of significant sample
loss with low recovery. Thus, if the target cargo is of low quantity
within the sample or if the sample size is limited, the “gold-
standard” isolation methods may not be the most appropriate
experimental approach. Ultracentrifugation may also result in
damage to the vesicle shape or structure, which would impact
subsequent use for further studies (e.g., to determine target cell
integration following EV injection in vivo). In addition to cent-
rifugation, other methods, such as immunoprecipitation or
antibody-based sorting, can also result in selective enrichment of
certain populations of EVs or cargo, leading to biased sampling
(Mateescu et al., 2017). Immunoprecipitation has further been
found to allow for extraction of non-EV constituents of the sam-
ple (The´ry et al., 2018). Moreover, disproportionate representa-
tion of EV subpopulation cargo may be amplified with certain
techniques, such as biased amplification and detection of RNA
transcripts with current RNAseq platforms. However, compari-
sons across experimental conditions can be performed when fac-
toring in the potential for bias, as all group conditionswould have
undergone similar processing and analysis, although it should
still be acknowledged that a target of interest may not be accu-
rately represented based on these limitations.
The potential for variability both within and across platforms
also introduces concern for accurate data interpretation when
analyzing multiple samples. A recent study demonstrated vari-
ability of EV quantification with nanoparticle tracking when us-
ing standardized settings on two different instruments, but this
variability was reduced by optimizing settings on an instrument-
specific basis (Vestad et al., 2017). These data highlight the im-
portance of analyzing all samples for a given study under tightly
controlled conditions on the same instrument, which represents
a significant challenge for longitudinal studies. Furthermore,
nanoparticle tracking detects any particle within a given size
range; thus, the data may not only be representative of EV popu-
lations. Therefore, validation across technical platforms should
be incorporated into experimental design as a further means to
validate conclusions.
EV cargo quantification
After isolating EVs, assessment of cargo is often conducted to
elucidate changes in EV-specific signaling factors. However, the
selection of a reference RNA or protein as a normalization factor
has remained a concerning issue for interpretation of data since
variable levels of RNAs and proteins are found under baseline
conditions. For instance, to quantify protein levels in brain tissue,
-actin is often used as the reference to adjust for differences in
the number of cells collected between subjects; however, such a
universally accepted reference has not been consistently ascer-
tained for biofluids. Conceptually, if an increase in the number of
EV-encapsulated miRNAs occurs following a stimulus, the most
appropriate reference would be a miRNA that is found in high
abundance in the biofluid and that is unaltered by the specific
experimental stimulus.Without anappropriate referencemiRNA, it
is unclear as to how to control for differences based on unavoid-
able variation in sampling between subjects. To address this issue,
some investigators have chosen to normalize to total RNA
counts, total protein levels, or EV density, but each of these ap-
proaches often leads to different data endpoints and, thus, ques-
tionable conclusions. With regard to an appropriate singular
reference RNA for qRT-PCR quantification, some in the field use
U6, but there is evidence that U6 can have variable expression in
biofluid samples (Xiang et al., 2014). This has led others to pro-
pose averaging multiple putative reference miRNAs together to
ascertain an average background level of expression or estimating
the total number of EVs in a sample (Akers et al., 2013; Gouin et
al., 2017), but these approaches may still lead to biased findings
depending on the miRNAs selected or EV quantificationmethod
used, respectively.
When changes are found in EV characteristics and/or cargo
following an experimental stimulus or between disease condi-
tions in vivo, any identified difference(s) could feasibly be the
result of a variety of mechanisms, including cell population of
origin, preferential loading of certain cargo, release dynamics,
and/or kinetics associated with cell type-specific uptake. Thus,
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interpretation of the relevance of any detected change may be
based on speculative assertations, rather than definitive conclu-
sions. By validating in vivo findings with more experimentally
controlled in vitro conditions, individual processes can be dis-
cretely isolated and assessed with a higher level of confidence.
However, established findings in the field should guide in vitro
experimental design. For instance, many earlier publications
used FBS in cell culture experiments; however, FBS has been
found to contain bovine EVs/RNAs that have contaminated re-
sults (Wei et al., 2016; Kornilov et al., 2018). Second, the forma-
tion of nanotubules can occur in culture conditions, which allow
for the transfer of materials between cells; this transfer process
could confound investigations seeking to demonstrate EV cell-
to-cell communication (McCoy-Simandle et al., 2016). Third,
strategies to identify EVs via lipophilic dye labeling have been
shown to lead to fluorescent dye transfer out of labeled EVs and
into other cells (Takov et al., 2017), resulting in incorrect assess-
ment of EV number and target cell integration. As the field con-
tinues to evolve, a set of guidelines to establish “minimal
information for studies of extracellular vesicles” was put forth to
provide specific criteria to enhance rigor for EV studies and to
provide a foundation for comparisons across the field (Lo¨tvall et
al., 2014; The´ry et al., 2018).
Further considerations for brain-derived circulating EVs
Various approaches have been used to assess and characterize
EVs selectively derived from cells in the brain. For instance, CSF
has been collected and analyzed to examine EVs localized within
the intracerebral space. However, it is often challenging to obtain
a pure sample because techniques to access the interstitial fluid of
the brain or spinal cord can induce puncture of blood vesicles,
resulting in blood-derived EV contamination. To overcome this
issue, chronic indwelling implants may be used to collect small
samples over time. Unfortunately, in rodents, the size of the sam-
ple continues to be a limiting factor for further analysis because
many EV assays require milliliters of fluid, whereas only a few
microliters may be obtained at a time with this method. Alter-
natively, CSF may be obtained from the cisterna magna after
carefully dissecting and removing muscle covering the outer
membrane at the base of the skull; when performed precisely, this
method allows for collection of pure CSF without blood contam-
ination. While relatively larger samples can be obtained with this
technique in rodents, it is a terminal procedure that still only
yields microliter-range sample sizes (e.g.,10–15 l frommice,
100–200l from rats). In humans, ventriculoperitoneal shunts
may be implanted under pathological conditions to allow for CSF
collection over time, but comparison control samples to account
for changes with the disease state are more difficult to obtain due
to safety issues based on the invasive nature of the procedure for
healthy subjects. Moreover, the location of sample collection has
been shown to lead to differences in EV RNA content (Akers et
al., 2013), thus imposing additional challenges to ensure experi-
mental rigor.
Extraction methods have also been developed to derive EVs
from the extracellular (nonventricular) space surrounding neu-
rons by dissecting brain tissue and processing to isolate EV pop-
ulations (Gallart-Palau et al., 2016; Vella et al., 2017). This
technical approach may seek to limit intracellular contamina-
tion, but damage to cell membranes with dissection is unavoid-
able and thus induces the release of intracellular vesicles and/or
leads to the artificial creation of vesicles (e.g., synaptosome-like
vesicles). Consequently, enrichment, rather than purification, is
more specifically obtained with current approaches (Vella et al.,
2017), a consideration that must be addressed when interpreting
experimental findings.
While EVs in the brain are thought to mainly contribute to
intercellular neural signaling, it is likely that either (1) excess EVs
are released, leading to the need for filtration and elimination
from the body, and/or (2) neural-derived EVs may be incorpo-
rated into peripheral cells to modulate their function. For this to
occur, EVs would have to pass through the BBB. While the exact
mechanisms of active or passive transport across this barrier are
largely unknown, there is evidence that this does indeed occur.
For instance, intravenously administered EVs have been shown
to enter into the neural parenchyma (Alvarez-Erviti et al., 2011);
and conversely, altered expression of EVs is found in blood sam-
ples from patients with CNS neurological disease (Burgos et al.,
2014). Together, these findings provide evidence for the recip-
rocal passage of EVs between the brain and blood. However,
the selective isolation of neural-derived EVs in peripheral bio-
fluids is currently not feasible given the lack of a neuron-
specific biomarker. Indeed, proposed “neuron-derived”
markers (e.g., L1CAM or NCAM) are not necessarily neuron
specific. Cross-referencing these markers to protein expres-
sion patterns in peripheral organs (e.g., via databases, such as
www.proteinatlas.org) provides evidence that EVs with these
markers could have originated from peripheral tissues.
Since the identification and detection of EVs in the urine or
blood hold promise to elucidate biomarkers of neural signaling
or pathological states, studies are being conducted to establish a
correlation between brain state and peripheral EV population
characteristics. However, collection/processing of urine or blood
can introduce contaminating factors, such as bacteria or an acti-
vated immune response, respectively. If urine is not sterile-
filtered a short period of time after collection, bacteria-derived
EVsmay be introduced into the sample and thereby contaminate
analyses. When handling blood, the extraction and processing
can lead to platelet contamination and/or immune cells can be
artificially induced to release EVs that were not present in the
fluid at the time of blood collection (Mitchell et al., 2016). Fur-
thermore, consistent processing protocols need to be imple-
mented to allow for confidence in the findings with comparisons
of samples. For instance, after collection of a large volume of CSF
from a human, samplesmay undergo repeated freeze-thaw cycles
each time a smaller amount is extracted to obtain multiple data
points, such as to conduct various technical analyses (e.g., EM,
EV quantification, RNA analysis, protein analysis, etc.) or to
compile repeated assessments for a longitudinal study. However,
repeated freeze-thaw cycles have been shown to be especially det-
rimental to sample integrity (Yuana et al., 2015; Akers et al.,
2016).
The dynamics associated with EV signaling also introduce
question for our ability to derive firm conclusions based on as-
sessment of EV number and/or cargo in a biological sample. For
example, an increase in the number of EVs is not necessarily
indicative of increased parental cell EV release. Rather, it may be
attributable to a decrease in EV uptake into target cells. Con-
versely, a decrease in EV density could be indicative of decreased
release from parental cells, increased uptake by target cells,
and/or increased export out of the brain. All of these factors are
influenced by sample collection time point relative to the ex-
perimental manipulation, as well as largely undefined time-
dependent factors, such as those involved in cell-specific EV bio-
genesis, release, and uptake.
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EV delivery into the brain
In addition to the assessment of EVs derived from the neural
domain, the generation of EVs for directed delivery of therapeu-
tic molecules or drug compounds into the brain is a quickly
advancing area within the field (Lakhal andWood, 2011; García-
Manrique et al., 2018; Zhu et al., 2018). In support of this thera-
peutic approach, systemic injections of EVs derived from
mesenchymal stromal cells were found to enhance neural recov-
ery after ischemic stroke in rats (Xin et al., 2013). Such a strategy
has tremendous therapeutic potential if cell type-specific integra-
tion can be achieved via external targeting motifs. However,
skepticism is present for whether this approach can be success-
fully applied in a clinically relevant setting. First, given that EVs
are only40 nm to 1 m in size, the type and amount of cargo
able to be loaded are limited; and therefore, therapeutic ap-
proaches may need to be in the nanoscale range. To date, engi-
neered EVs have successfully been loaded with 70–250 kDa
molecules, although the currentmethods have had low success in
generating a large yield of viable EVs (Antimisiaris et al., 2018).
Second, the targeted deliverymethodmust be validated for selec-
tivity and off-target effects. For example, because peripheral in-
jection for subsequent integration across the BBB would be
preferred (e.g., as opposed to intracerebroventricular injection),
the quantity of EVs injected will likely need to be tightly con-
trolled to prevent adverse effects resulting fromEV accumulation
and/or breakdown in peripheral organ systems. Further, a large
number of injected EVs will be required to obtain adequate infil-
tration into the brain, until mechanisms to promote passage
through the BBB are more clearly defined and exploited.
Future outlook and perspectives to advance the EV field
To achieve rigor and reproducibility in the field, validation of
techniques to obtain, analyze, and interpret EV data from the
extracellular environment will need to continue evolving as vary-
ing types of samples are targeted for experimentation. Biased, but
replicable, assessments may be an appropriate starting point for
some studies with inherent technical limitations. Cross-platform
validation should also be incorporated to support conclusions,
when possible. Another goal is to be better able to obtainmultiple
data points from the same sample, such as density and size quan-
tification paired with subsequent analysis of cargo content, or
alternatively, the ability to maintain EV integrity for injection in
vivo following various isolation methods. Along these lines, the
ability to probe for a variety of EV content, including multiple
RNA species, RNA binding proteins, DNA, enzymes, and other
proteins, in a cell type- and stimulus-specific manner will be
important to fully understand the various functions of this type
of extracellular communication. Of note, the National Institutes
of Health Common Fund Extracellular RNA Communication
Program has developed an exRNA online resource portal (www.
exrna.org), which provides searchable datasets for different bio-
fluids derived from individuals characterized as “normal” or di-
agnosed with disease, a software pipeline to analyze EV datasets,
metadata standards to allow informative labeling of EV datasets,
protocols to standardize EV research, and EV-relevant resources,
such as plasmids, mice, and libraries. Open source depositing of
large datasets will continue to assist in defining specificity of
cargo and/or targeting motifs, especially when based on cell type
of origin and/or disease state, although this is dependent on con-
tinued support to maintain such efforts (e.g., www. exocarta.org
and www.microvesicles.org).
The field will also need to obtain a more systematic under-
standing of the biogenesis, packaging, release, and uptake time
courses for EVs derived from individual cell types. For instance,
future studies will need to define the relative time necessary to do
the following: (1) initiate intracellular signaling cascades to pro-
duce specific EV cargo, such as miRNAs, mRNAs, lncRNAs pro-
teins, enzymes, etc., (2) generate EV membranes as either
multivesicular bodies or via membrane blebbing, (3) shuttle sig-
naling factors to the EV location, (4) load EVs, (5) release EVs
into the extracellular environment, (6) uptake EVs by the recip-
ient cell, (7) degrade the EV membrane and process the EV con-
tents, and (8) exert an impact on the recipient cell’s function.
While several of these processes are beginning to become eluci-
dated, further validation will need to occur across cell types
and in vivo. Indeed, the ongoing development of transgenic
mouse lines to detect EVs released from target cell subpopu-
lations has the potential to lead to significant advances. Along
these lines, current National Institutes of Health funding ini-
tiatives are focused on the development of novel technologies
to catalyze discoveries and further expand our understanding
of EV-based communication.
In conclusion, EVs represent an exciting new direction for the
neuroscience field. As the field progresses, new discoveries will
further establish a greater understanding of these signaling com-
partments and their cargo, with the potential for broad signifi-
cance and inferences across neuroscience subfields. For instance,
it will truly be exciting to determine whether EV signaling mech-
anisms underlie brain development, homeostatic function, sen-
sory processing, motivated behaviors, and cognitive function, as
a few possibilities. Ultimately, the canonical characterization of
neural communication methods will likely have to be expanded
beyond electrical, chemical, and hormonal mechanisms to now
include EV signaling mechanisms.
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